Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App





Preventive COVID-19 Peptide Vaccine Aims to Provide Broad and Long-Lasting Immune Response

By HospiMedica International staff writers
Posted on 17 Jun 2020
Scientists have developed and successfully tested in silico a preventive COVID-19 peptide vaccine which is designed to elicit long-term T cell immunity in contrast to most of the vaccine candidates being developed with antibodies.

The preventive vaccine product, PolyPEPI-SCoV-2, has been developed by Treos Bio Limited (London, UK) using its proprietary, computational vaccine design technology. More...
The company has transferred all rights, including pending patent applications, for the preventive COVID-19 peptide vaccine to a newly-formed subsidiary, PepTC Vaccines Limited (London, UK).

PepTC Vaccines’ PolyPEPI-SCoV-2 investigative vaccine consists of 10 different, 30-amino acid long synthetic peptides. To design its experimental SARS-CoV-2 vaccine, Treos took into consideration both the data obtained from patients who recovered from the previous coronavirus (SARS-CoV) epidemy in 2003 and other information specific to variants of the current coronavirus. Treos selected peptide fragments of the conserved regions of the presently known multiple viral structural protein sequences as well as multiple shared personal epitopes (PEPIs) of subjects with different ethnicities for its model population. Epitope selection was directed toward both HLA class I and HLA class II specific PEPIs to induce robust T cell responses that will establish memory T cell pools.

In silico preclinical testing of the PolyPEPI-SCoV-2 vaccine in diverse ethnic groups of approximately 16,000 HLA genotyped subjects from a US bone marrow donor database, resulted in an equally high proportion of subjects showing both CD8+ and CD4+ T cell responses in each ethnic group. PepTC Vaccines expects to advance to human clinical studies for its investigational PolyPEPI-SCoV-2 vaccine by October 2020 and announce preliminary trial results in March 2021. PepTC Vaccines’ approach provides cost-effective and immediately scalable manufacturing since it relies on well-established, accessible manufacturing technology and widely available chemicals to produce the synthetic peptides used in Treos’ immunotherapies.

“Our efforts are focused on the development of an effective, safe, and potentially best-in-class vaccine against SARS-CoV-2. We are addressing the challenges of the heterogeneity of individuals’ immune response, the potential for structural variations in the infecting virus, and the observed phenomenon of long-term immunity to coronaviruses likely stemming from T cell activity,” said Dr. Christopher C. Gallen, Executive Chairman of Treos. “Based on our clinical experience with our PolyPEPI peptide immunotherapy in metastatic colorectal cancer patients and our validated in silico human model, we believe that our approach has the potential to provide a broad and long-lasting immune response, independent of gender, age, or ethnicity, and be able to protect people worldwide against COVID-19.”

“We anticipate that as the coronavirus continues to evolve and as more data are collected, additional mutations will be observed. Such mutations will not affect the global coverage of our vaccine, provided that they occur outside of the identified epitope regions,” said Enikő R. Tőke, Ph.D., Chief Scientific Officer for Treos. “If mutations do occur within any of the epitope regions selected, then the intact immunogenic epitopes could still provide protection against the virus since a majority of the subjects will still have a broad repertoire of virus-specific memory T cell clones.”

Related Links:
Treos Bio Limited
PepTC Vaccines Limited



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Hand-held Hemoglobin Analyzer
DiaSpect Tm
Syringe Pump
SP50 Series
Breast Imaging Monitor
Barco Coronis Onelook MDMC-32133 32MP
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Design-science framework integrating CML and LLM pipelines for supply chain risk evaluation. (Gupta I, Konduru H, Correa S, et al. A causal analytics approach for interpretable supply chain risk and supplier performance evaluation. Supply Chain Analytics, 2026. doi:10.1016/j.sca.2026.100248)

Causal AI Tool Withholds Ovarian Cancer Treatment Recommendations When Evidence Insufficient

Ovarian cancer treatment often requires individualized decisions, particularly when available patient data do not clearly favor one therapeutic approach. However, artificial intelligence (AI) systems may... Read more

Patient Care

view channel
Image: A view inside the custom virtual reality environment used in the study: a calm room with a teddy bear, soft colors and large windows looking out over the sea. (Image Credit: Walaa S. Abu Rukbah et al., Virginia Commonwealth University; CC-BY 4.0, https://creativecommons.org/licenses/by/4.0/)

Virtual Reality Program May Reduce Anxiety Before Pediatric Surgery

Presurgery anxiety affects an estimated 50% to 75% of children undergoing surgery and can complicate anesthesia induction, increase postoperative pain, and prolong recovery. Sedation is often used to manage... Read more

Medical Imaging

view channel
Image Credit: Adobe Stock

Lung Ultrasound Predicts Progression of Interstitial Lung Abnormalities in Rheumatoid Arthritis

Interstitial lung abnormalities are a pulmonary concern in patients with rheumatoid arthritis, requiring monitoring to detect disease progression. However, tracking these changes often involves repeated... Read more

Point of Care

view channel
Image: Jessica Ramella-Roman, professor of biomedical engineering at Florida International University, holding the PPRIM (Portable Preterm Imaging) device designed to detect early signs of preterm labor risk. (Photo courtesy of Florida International University)

Handheld Imaging Device May Help Identify Preterm Birth Risk Earlier

Preterm birth, defined as delivery before 37 weeks of pregnancy, can lead to serious neonatal complications, including neurological, developmental, and respiratory problems. However, identifying pregnancies... Read more

Business

view channel
Image: Stryker has acquired ZuriMED, adding the FiberLocker System, a rotator cuff augmentation technology designed to strengthen repairs, to its Sports Medicine portfolio. (Photo courtesy of ZuriMED)

Stryker Completes Acquisition to Broaden Shoulder Surgery Offerings

Stryker (Portage, MI, USA) has completed its acquisition of ZuriMED (Zurich, Switzerland), a privately held developer of the FiberLocker System, expanding its Sports Medicine portfolio with a commercialized... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.